Nortriptyline has not been proven safe during pregnancy, but it is not strictly off-limits either. The official prescribing label states that safe use in pregnancy “has not been established,” and the decision comes down to weighing the benefits of staying on the medication against the potential risks to the baby. For many women, untreated depression carries its own serious risks, which is why doctors sometimes recommend continuing nortriptyline through pregnancy rather than stopping it abruptly.
What the Evidence Shows About Birth Defects
The largest dataset on first-trimester nortriptyline exposure looked at 1,381 pregnancies. Among those, 8.9% of infants had some type of congenital condition, with an odds ratio of 1.2, meaning the risk was only slightly above the general population baseline of roughly 3% to 5% for major malformations. That modest increase has not been consistently replicated, and the data doesn’t clearly separate nortriptyline’s effects from the effects of the underlying condition being treated.
When researchers looked at tricyclic antidepressants as a whole class (not nortriptyline alone), they found statistically significant increases in digestive system malformations and abnormalities of the eyes, ears, face, and neck. These were uncommon even in the exposed group, but the signal was strong enough to warrant attention. The key takeaway: nortriptyline does not appear to be a major cause of birth defects, but a small added risk has not been ruled out.
Risks of Late Pregnancy Exposure
Taking nortriptyline in the third trimester raises a separate set of concerns. Newborns exposed to antidepressants late in pregnancy have a higher rate of respiratory distress. One large study found the odds of breathing difficulties were nearly doubled even after excluding premature births (odds ratio 1.81). These episodes are typically manageable in a hospital setting, but they can mean extra monitoring or a short stay in a neonatal unit.
Babies born to mothers on tricyclic antidepressants can also experience a brief withdrawal-like reaction after delivery. Symptoms include jitteriness, tremors, high-pitched crying, poor feeding, and disrupted sleep. In most cases, these signs appear within the first day or two of life and resolve on their own within hours to days. Severe complications from this adaptation syndrome are rare, but your delivery team should know about the medication so they can watch for it.
What Happens If Depression Goes Untreated
The comparison isn’t simply “medication risk vs. no risk.” Untreated maternal depression is linked to premature birth, low birth weight, restricted fetal growth, and a higher rate of pregnancy complications including preeclampsia. Women with untreated depression also face more hospital admissions during pregnancy. These outcomes can have lasting effects on a child’s development, which is why stopping a medication that’s working isn’t always the safer choice.
The American College of Obstetricians and Gynecologists recognizes tricyclic antidepressants, including nortriptyline, as appropriate options for treating depression during the perinatal period. Their clinical practice guideline places tricyclics alongside SSRIs and SNRIs as acceptable pharmacologic treatments when the clinical situation calls for them.
Your Body Processes It Differently While Pregnant
Pregnancy changes how your liver metabolizes nortriptyline. By the third trimester, blood levels of the drug drop to roughly half of what they were before pregnancy, even at the same dose. This happens because a key liver enzyme responsible for breaking down nortriptyline becomes significantly more active during pregnancy. The practical result is that a dose that worked well before pregnancy may stop being effective as the months go on, particularly in the final trimester, which is already a high-risk window for depression relapse.
Nortriptyline has a relatively narrow therapeutic range (the gap between “not enough” and “too much” is small), so these shifts matter more than they would with some other medications. Regular blood level monitoring throughout pregnancy allows your prescriber to adjust the dose and keep it in the effective range. After delivery, when your metabolism returns to its pre-pregnancy state, the dose typically needs to come back down to avoid side effects.
Breastfeeding on Nortriptyline
Nortriptyline is considered one of the more breastfeeding-compatible antidepressants. An exclusively breastfed infant receives roughly 1.3% of the mother’s weight-adjusted dose, which is well below the 10% threshold generally considered concerning. In pooled data from 32 mother-infant pairs, the drug was usually undetectable in infant blood, though less active breakdown products sometimes appeared at very low levels.
Only 1 of those 32 infants had a plasma level above 10% of the mother’s, the cutoff researchers defined as elevated. No adverse effects in breastfed infants have been consistently reported at standard maternal doses of 75 to 150 mg daily. For women who need to stay on an antidepressant while nursing, nortriptyline is often a reasonable choice precisely because so little reaches the baby.
Making the Decision
There is no risk-free option here. Continuing nortriptyline carries small, measurable risks to the baby, particularly respiratory issues at birth and the possibility of a brief neonatal adjustment period. Stopping the medication risks a depressive relapse that can harm both you and the pregnancy. Switching to a different antidepressant introduces its own transition period and may not offer a clearly better safety profile.
The factors that tip the decision one way or another include how severe your depression is, how well nortriptyline controls it, whether you’ve tried other antidepressants before, and how far along you are. Women who have been stable on nortriptyline and have a history of serious depression that didn’t respond to other medications are generally the strongest candidates for continuing it. If nortriptyline is being used for a condition with more treatment alternatives, like nerve pain or migraine prevention, the calculus shifts because there may be options with more pregnancy safety data.